3rd Quarter - Report

AMERICAN SOCIETY FOR CLINICAL PATHOLOGY for AMERICAN SOCIETY FOR CLINICAL PATHOLOGY

Firm
Client
Income
—
Expenses
$46,000
Expense method
B: tax-exempt organisations, Internal Revenue Code section 6033(b)(8)

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Labor Issues/Antitrust/Workplace LBR

Physician, clinical laboratory professional, and allied health workforce issues, Federal Funding for Education, Student loan Repayment/Forgiveness, and Related Workforce Development; Workforce Reinvestment Act; Federal Healthcare Workforce Issues; Appropriations for Federal Agencies; Clinical Laboratory Improvement Amendments; COVID-19 Response and Laboratory Test Capacity; immigration issues impacting laboratory workforce

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Bureau of Citizenship & Immigration Services (BCIS); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); Education, Dept of; Food & Drug Administration (FDA); Veterans Affairs, Dept of (VA); Homeland Security, Dept of (DHS)

Health Issues HCR

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Stark Self-Referral Reform; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments ; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; federal oversight of laboratory tests including laboratory developed testing services; immigration

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: U.S. Immigration & Customs Enforcement (ICE); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Homeland Security, Dept of (DHS); Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC)

Medical/Disease Research/Clinical Labs MED

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform; the RESULTS Act

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE; Centers For Medicare and Medicaid Services (CMS); Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS)

Medicare/Medicaid MMM

Medicare; Electronic Health Records/Health Information Technology; Medicare Access and CHIP Reauthorization; Protecting Access to Medicare Act; Medicare Physician and Clinical Laboratory Fee Schedules; Medicare Quality Payment Program; Medicare National and Local Coverage Determinations; Federal Oversight of Laboratory Tests including Laboratory Developed Testing Services; Physician and Clinical Laboratory Personnel Shortages/workforce issues; Education and Loan Repayment Programs; Appropriations for Federal Agencies; Global Health Initiative; Laboratory Access for Beneficiaries Act; Clinical Laboratory Improvement Amendments; Laboratory oversight; COVID-19 Response and Laboratory Testing Capacity; Communicable Diseases and Pandemic Preparedness; Stark Self-Referral Reform; the RESULTS Act

LobbyistCovered position, as disclosed
MATTHEW SCHULZE —

Contacted: Food & Drug Administration (FDA); SENATE; Health & Human Services, Dept of (HHS); Bureau of Labor Statistics (BLS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.